Aspen Pharmacare (NASDAQ:APNHY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. The firm presently has a $25.00 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 9.82% from the stock’s current price.
According to Zacks, “Aspen Pharmacare Holdings Limited provide specialty, branded and generic pharmaceuticals for acute and chronic conditions. It operates primarily in Sub-Saharan Africa, Latin America, South East Asia and Eastern Europe. Aspen Pharmacare Holdings Limited is headquartered in Durban, South Africa. “
Shares of Aspen Pharmacare (NASDAQ:APNHY) opened at 22.765 on Thursday. Aspen Pharmacare has a 52 week low of $18.75 and a 52 week high of $24.30. The stock has a market cap of $10.38 billion and a PE ratio of 26.348. The company’s 50-day moving average is $22.98 and its 200 day moving average is $21.80.
TRADEMARK VIOLATION NOTICE: “Aspen Pharmacare (APNHY) Stock Rating Upgraded by Zacks Investment Research” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/10/28/aspen-pharmacare-apnhy-stock-rating-upgraded-by-zacks-investment-research.html.
Receive News & Ratings for Aspen Pharmacare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Pharmacare and related companies with MarketBeat.com's FREE daily email newsletter.